Cash, cash equivalents, and marketable securities totaled approximately $319.5 million as of June 30, 2025.
FILSPARI net product sales reached approximately $72 million in the U.S., representing significant year-over-year growth of about 82%.
License and collaboration revenue included a one-time $17.5 million milestone payment from CSL Vifor due to full approval of FILSPARI in Europe.
Net loss narrowed significantly to $12.8 million or $0.14 per share from $70.4 million or $0.91 per share in the prior year period.
On a non-GAAP basis, net income was $11.9 million or $0.13 per share compared to a net loss of $50.1 million previously.
Research and development expenses decreased to $49.4 million from $54.3 million year-over-year, reflecting reduced clinical activity in the Phase III HARMONY study.
Selling, general, and administrative expenses increased to $76.2 million from $64.8 million, driven by amortization of FILSPARI royalties and investments in launch and preparation for FSGS.
THIOLA and THIOLA EC contributed $23 million in net product sales, though generic competition is anticipated in coming quarters.
Travere Therapeutics reported strong Q2 2025 financial results with total revenue of $114.4 million, including $94.8 million in U.S. net product sales.
Expenses aligned with expectations as the company fully transitioned into commercialization mode.
Liquidia closed Q2 2025 with $173 million in cash and cash equivalents, supporting ongoing commercialization and pipeline investments.
Q2 revenue totaled $8.8 million, including $6.5 million from YUTREPIA product sales and $2.3 million from treprostinil injection promotion services with Sandoz.
R&D expenses are expected to increase in the second half of 2025 due to ongoing label studies and initiation of the pivotal L-606 study.
SG&A expenses, excluding noncash and variable treprostinil costs, are expected to remain flat in upcoming quarters.
Dafinchi